Viatris is trading 4.2% down at $16.91 after investors appeared to weigh second-half risks tied to China, supply disruptions, and competition despite stronger-than-expected second-quarter results.
- Adjusted EPS rose 11% to $0.69; revenue increased 5% to $3.8 billion, and full-year guidance was raised.
- The GAAP loss included a $177.8 million non-cash Tyrvaya-related charge.
- Reported volume was 11.35 million shares versus a 10.88 million 65-day average.